Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma.

9510Background: The BRIM7 study (ClinicalTrials.gov ID, NCT01271803) evaluated the safety and preliminary efficacy of C+V (Ribas A et al. Lancet Oncol. 2014;15:954-965.); a subsequent randomized ph...